Homology Medicines to merge with Q32 Bio; Q32 shareholders to own 75%, combined company targets autoimmune pipeline

Q32 Bio Inc.

Homology issues stock to Q32 holders; pre-merger Homology shareholders own ~25%, Q32 ~75%; CVR issued for legacy asset proceeds.
Concurrent $42M private placement (OrbiMed, Atlas, Bristol Myers Squibb, etc.) to fund Phase 2 trials of bempikibart and ADX-097.
Combined company expects ~$115M cash at close, runway to mid-2026; Homology discontinues R&D, including PKU gene therapy HMI-103.
Q32 reacquired worldwide rights to bempikibart (anti-IL-7Rα) from Amgen; Phase 2 topline data for atopic dermatitis & alopecia areata in 2H 2024.
ADX-097 (tissue-targeted complement inhibitor) Phase 1 safety positive; Phase 2 basket trial start expected with proof-of-concept data by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.